Skip to main content
SpringerLink
Log in

Hepatocellular Carcinoma

  • Chapter
  • First Online:
Oncology in the Precision Medicine Era

  • 810 Accesses

Abstract

Liver cancer is the second leading cause of cancer deaths worldwide, with hepatocellular carcinoma (HCC) comprising approximately 90% of all cases. Many key signaling pathways including mitogen-activated protein kinases (MAPK), growth factors, mammalian target of rapamycin (mTOR), β-catenin, and Hedgehog are known to influence the development of HCC. While numerous targeted therapies have been studied in clinical trials for the treatment of HCC, sorafenib, regorafenib, nivolumab and most recently, lenvatinib are the only FDA-approved treatments for the disease. There is evidence to suggest that genomic profiling of individual patient tumors can provide physicians with insight into the best course of treatment including novel targeted therapies. Increased genomic profiling of patient tumors in the future may contribute to a more effective and individualized approach to the management of HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.

    Article  PubMed  Google Scholar 

  2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.

    Article  CAS  PubMed  Google Scholar 

  3. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14.

    Article  PubMed  Google Scholar 

  4. Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9(6):765–79. PubMed PMID: 25827821. Epub 2015/04/02. eng.

    Article  CAS  PubMed  Google Scholar 

  5. Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol. 2016;34(15):1787–94. PubMed PMID: PMC4966339.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60(5):1767–75. PubMed PMID: PMC4211957.

    Article  PubMed  Google Scholar 

  7. Klungboonkrong V, Das D, McLennan G. Molecular mechanisms and targets of therapy for hepatocellular carcinoma. J Vasc Interv Radiol. 2017;28(7):949–55. PubMed PMID: 28416267. Epub 2017/04/19. eng.

    Article  PubMed  Google Scholar 

  8. Delire B, Starkel P. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. Eur J Clin Investig. 2015;45(6):609–23. PubMed PMID: 25832714. Epub 2015/04/03. eng.

    Article  CAS  Google Scholar 

  9. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 2006;25:3787.

    Article  CAS  PubMed  Google Scholar 

  10. Giordano S, Columbano A. Met as a therapeutic target in HCC: facts and hopes. J Hepatol. 2014;60(2):442–52. PubMed PMID: 24045150. Epub 2013/09/21. eng.

    Article  CAS  PubMed  Google Scholar 

  11. Akhtar B, Muhammad F, Sharif A, Akhtar MF, Majeed W. Diverse signaling pathways and current status of molecular targeted treatments for hepatocellular carcinoma. Crit Rev Eukaryot Gene Expr. 2017;27(4):373–85. PubMed PMID: 29283332. Epub 2017/12/29. eng.

    Article  PubMed  Google Scholar 

  12. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterol. 2008;135(6):1972–83. PubMed PMID: PMC2678688.

    Article  CAS  Google Scholar 

  13. Waisberg J, Saba GT. Wnt-/-β-catenin pathway signaling in human hepatocellular carcinoma. World J Hepatol. 2015;7(26):2631–5. PubMed PMID: PMC4651907.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Wang W, Pan Q, Fuhler GM, Smits R, Peppelenbosch MP. Action and function of Wnt/β-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma. J Gastroenterol. 2017;52(4):419–31. PubMed PMID: PMC5357489.

    Article  CAS  PubMed  Google Scholar 

  15. Della Corte CM, Viscardi G, Papaccio F, Esposito G, Martini G, Ciardiello D, et al. Implication of the Hedgehog pathway in hepatocellular carcinoma. World J Gastroenterol. 2017;23(24):4330–40. PubMed PMID: PMC5487497.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Zheng X, Zeng W, Gai X, Xu Q, Li C, Liang Z, et al. Role of the hedgehog pathway in hepatocellular carcinoma (review). Oncol Rep. 2013;30(5):2020–6. PubMed PMID: 23970376. Epub 2013/08/24. eng.

    Article  CAS  PubMed  Google Scholar 

  17. Sachdeva M, Chawla YK, Arora SK. Immunology of hepatocellular carcinoma. World J Hepatol. 2015;7(17):2080–90. PubMed PMID: PMC4539401.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Nishida N, Kudo M. Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. Hepatology research: the official journal of the Japan society of. Hepatology. 2018;48(8):622–34. PubMed PMID: 29734514. Epub 2018/05/08. eng.

    Article  CAS  Google Scholar 

  19. European Association for the Study of the L, European Organisation for R, Treatment of C. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.

    Article  Google Scholar 

  20. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. PubMed PMID: 18650514. Epub 2008/07/25. eng.

    Article  CAS  PubMed  Google Scholar 

  21. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. PubMed PMID: 19095497. Epub 2008/12/20. eng.

    Article  CAS  PubMed  Google Scholar 

  22. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31(32):4067–75. PubMed PMID: 24081937. Epub 2013/10/02. eng.

    Article  CAS  PubMed  Google Scholar 

  23. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013;31(28):3517–24. PubMed PMID: 23980084. Epub 2013/08/28. eng.

    Article  CAS  PubMed  Google Scholar 

  24. Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31(28):3501–8. PubMed PMID: 23980077. Epub 2013/08/28. eng.

    Article  CAS  PubMed  Google Scholar 

  25. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol. 2013;31(28):3509–16. PubMed PMID: 23980090. Epub 2013/08/28. eng.

    Article  CAS  PubMed  Google Scholar 

  26. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA. 2014;312(1):57–67. PubMed PMID: 25058218. Epub 2014/07/25. eng.

    Article  PubMed  CAS  Google Scholar 

  27. Zhu AX, Park JO, Ryoo B-Y, Yen C-J, Poon R, Pastorelli D, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16(7):859–70.

    Article  CAS  PubMed  Google Scholar 

  28. Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(6):559–66. PubMed PMID: 25547503. Epub 2014/12/31. eng.

    Article  CAS  PubMed  Google Scholar 

  29. Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33(2):172–9. PubMed PMID: 25488963. Pubmed Central PMCID: PMC4279237. Epub 2014/12/10. eng.

    Article  CAS  PubMed  Google Scholar 

  30. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. PubMed PMID: 27932229. Epub 2016/12/10. eng.

    Article  CAS  PubMed  Google Scholar 

  31. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73. PubMed PMID: 29433850. Epub 2018/02/13. eng.

    Article  CAS  PubMed  Google Scholar 

  32. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63. PubMed PMID: 29972759. Epub 2018/07/05. eng.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018;19(5):682–93. PubMed PMID: 29625879. Epub 2018/04/08. eng.

    Article  CAS  PubMed  Google Scholar 

  34. Zhu AX, Kang Y-K, Yen C-J, Finn RS, Galle PR, Llovet JM, et al. REACH-2: a randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. J Clin Oncol. 2018;36(15_suppl):4003.

    Article  Google Scholar 

  35. Yang S, Liu G. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett. 2017;13(3):1041–7. PubMed PMID: PMC5403244.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Lou J, Zhang L, Lv S, Zhang C, Jiang S. Biomarkers for hepatocellular carcinoma. Biomark Cancer. 2017;9:1–9. PubMed PMID: PMC5345949.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Höpfner M, Schuppan D, Scherübl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol. 2008;14(1):1–14. PubMed PMID: PMC2673371.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14(1):55–63. PubMed PMID: 23182627. Epub 2012/11/28. eng.

    Article  CAS  PubMed  Google Scholar 

  39. Weekes CD, Clark JW, Zhu AX. Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target? Lancet Oncol. 2018;19(5):591–2. PubMed PMID: 29625880. Epub 2018/04/08. eng.

    Article  PubMed  Google Scholar 

  40. Matter MS, Decaens T, Andersen JB, Thorgeirsson SS. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol. 2014;60(4):855–65.

    Article  CAS  PubMed  Google Scholar 

  41. Vilchez V, Turcios L, Marti F, Gedaly R. Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol. 2016;22(2):823–32. PubMed PMID: PMC4716080.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48(4):1312–27.

    Article  CAS  PubMed  Google Scholar 

  43. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–52.

    Article  PubMed  Google Scholar 

  45. Finn RS, Ducreux M, Qin S, Galle PR, Zhu AX, Ikeda M, et al. IMbrave150: a randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma. J Clin Oncol. 2018;36(15_suppl):TPS4141.

    Article  Google Scholar 

  46. Masafumi Ikeda, Max W Sung, Masatoshi Kudo, Masahiro Kobayashi, Ari David Baron, Richard S. Finn, Shuichi Kaneko, Andrew X. Zhu, Tomoki Kubota, Silvija Kraljevic, Kohei Ishikawa, Abby B. Siegel, Hiromitsu Kumada, Takuji Okusaka. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol 2018;36.

    Google Scholar 

  47. Agarwal R, Narayan J, Bhattacharyya A, Saraswat M, Tomar AK. Gene expression profiling, pathway analysis and subtype classification reveal molecular heterogeneity in hepatocellular carcinoma and suggest subtype specific therapeutic targets. Cancer Genet. 2017;216–217:37–51. PubMed PMID: 29025594. Epub 2017/10/14. eng.

    Article  PubMed  CAS  Google Scholar 

  48. Bruix J, Han K-H, Gores G, Llovet JM, Mazzaferro V. Liver cancer: approaching a personalized care. J Hepatol. 2015;62(1):S144–56.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Personeni N, Rimassa L. Hepatocellular carcinoma: a global disease in need of individualized treatment strategies. J Oncol Pract. 2017;13(6):368–9. PubMed PMID: 28605613. Epub 2017/06/13. eng.

    Article  PubMed  Google Scholar 

  50. Li H, Jiang X, Zhu S, Sui L. Identification of personalized dysregulated pathways in hepatocellular carcinoma. Pathol Res Pract. 2017;213(4):327–32. PubMed PMID: 28215647. Epub 2017/02/22. eng.

    Article  CAS  PubMed  Google Scholar 

  51. Ikeda S, Lim JS, Kurzrock R. Analysis of tissue and circulating tumor DNA by next-generation sequencing of hepatocellular carcinoma: implications for targeted therapeutics. Mol Cancer Ther. 2018;17(5):1114–22. PubMed PMID: 29483209. Pubmed Central PMCID: PMC5932233. Epub 2018/02/28. eng.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Posadas K, Ankola A, Yang Z, Yee NS. Tumor molecular profiling for an individualized approach to the treatment of hepatocellular carcinoma: a patient case study. Biomedicines. 2018;6(2). PubMed PMID: 29673151. Pubmed Central PMCID: PMC6027424. Epub 2018/04/21. eng.

    Article  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, CA, USA

    Rebecca Allen & Daneng Li

Authors
  1. Rebecca Allen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daneng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daneng Li .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA

    Ravi Salgia

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Allen, R., Li, D. (2020). Hepatocellular Carcinoma. In: Salgia, R. (eds) Oncology in the Precision Medicine Era. Springer, Cham. https://doi.org/10.1007/978-3-030-31471-2_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-31471-2_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-31470-5

  • Online ISBN: 978-3-030-31471-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation